title: Strategy to prevent recurrent portal vein stenosis following interventional radiology in pediatric liver transplantation.
abstract: Portal vein complications after liver transplantation (LT) are serious complications that can lead to graft liver failure. Although the treatment of interventional radiology (IVR) by means of balloon dilatation for portal vein stenosis (PVS) after LT is an effective method, the high rate of recurrent PVS is an agonizing problem. Anticoagulant therapy for PVS is an important factor for preventing short-term recurrence following IVR, but no established regimen has been reported for the prevention of recurrent PVS following IVR. In our population of 197 pediatric patients who underwent living donor liver transplantation (LDLT), 22 patients (22/197, 11.2%) suffered PVS. In the 9 earliest patients, unfractionated heparin was the only anticoagulant therapy given following IVR. In the 13 more recent patients, 3-agent anticoagulant therapy using low-molecular-weight heparin, warfarin, and aspirin was employed. In the initial group of 9 patients, 5 patients (55.6%) suffered recurrent PVS and required repeat balloon dilatation. Among the 13 more recent patients, none experienced recurrent PVS (P = 0.002). In conclusion, our 3-agent anticoagulant therapy following IVR for PVS in pediatric LDLT can be an effective therapeutic strategy for preventing recurrent PVS.
authors.affiliation: Department of Transplant Surgery, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke City, Tochigi, 329-0498 Japan. yuki371@jichi.ac.jp
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Sanada
authors.forename: Youichi
authors.initials: Y
authors.lastname: Kawano
authors.forename: Koichi
authors.initials: K
authors.lastname: Mizuta
authors.forename: Satoshi
authors.initials: S
authors.lastname: Egami
authors.forename: Makoto
authors.initials: M
authors.lastname: Hayashida
authors.forename: Taiichi
authors.initials: T
authors.lastname: Wakiya
authors.forename: Takehito
authors.initials: T
authors.lastname: Fujiwara
authors.forename: Yasunaru
authors.initials: Y
authors.lastname: Sakuma
authors.forename: Masanobu
authors.initials: M
authors.lastname: Hydo
authors.forename: Manabu
authors.initials: M
authors.lastname: Nakata
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Yasuda
authors.forename: Hideo
authors.initials: H
authors.lastname: Kawarasaki
mesh_terms: D000293:Adolescent; D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D002404:Catheterization; D002648:Child; D002675:Child, Preschool; D003251:Constriction, Pathologic / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D004359:Drug Therapy, Combination; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D016031:Liver Transplantation; D019520:Living Donors; D008297:Male; D011169:Portal Vein / Q000000981:diagnostic imaging / Q000503:physiopathology*; D011183:Postoperative Complications; D015642:Radiology, Interventional; D012039:Regional Blood Flow / Q000502:physiology; D012189:Retrospective Studies; D055502:Secondary Prevention; D016896:Treatment Outcome; D014463:Ultrasonography; D014652:Vascular Diseases / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D014859:Warfarin; D001241:Aspirin